OTC Drugs-Of-Abuse Assay Firms Should Provide Confirmatory Testing - Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA should require manufacturers of over-the-counter (OTC) screening tests for drugs-of-abuse to cover the cost of confirmatory testing for presumptive positive results, members of FDA's Clinical Chemistry and Clinical Toxicology Devices panel recommended.
You may also be interested in...
Flexible Approach Granted For Drugs-Of-Abuse Premarket Submissions
FDA's decision to allow alternatives to bundling confirmatory test costs with initial screening costs reflects greater flexibility in the agency's approach to premarket requirements for drugs-of-abuse tests, according to FDA
Flexible Approach Granted For Drugs-Of-Abuse Premarket Submissions
FDA's decision to allow alternatives to bundling confirmatory test costs with initial screening costs reflects greater flexibility in the agency's approach to premarket requirements for drugs-of-abuse tests, according to FDA
FDA Seeks Civil Money Penalties From Worldwide Medical, Firm's Executives
FDA affirmed its regulatory authority over home-use drugs-of-abuse assays in an October 1999 letter to Worldwide Medical that preceded its recent civil money penalty action against the firm, FDA reports.